These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 34259953)

  • 1. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis.
    Miyawaki T; Kenmotsu H; Yabe M; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Deguchi S; Mitsuya K; Naito T; Murakami H; Mori K; Harada H; Hayashi N; Takahashi K; Takahashi T
    Invest New Drugs; 2021 Dec; 39(6):1732-1741. PubMed ID: 34259953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
    Wu H; Zhang Q; Zhai W; Chen Y; Yang Y; Xie M; Huang Z; Xu Y; Li H; Gong L; Yu S; Fan Y; Chen K
    Lung Cancer; 2024 Feb; 188():107475. PubMed ID: 38266613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical outcomes of osimertinib and first-generation EGFR-tyrosine kinase inhibitors (TKIs) in TKI-untreated EGFR-mutated non-small-cell lung cancer with leptomeningeal metastases.
    Tamura K; Yoshida T; Masuda K; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y
    ESMO Open; 2023 Aug; 8(4):101594. PubMed ID: 37517364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases.
    Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B
    J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis.
    Wu Y; Zhao Y; Wu Y; Chen H; Ma S; Wang Q
    Clin Lung Cancer; 2024 Jun; 25(4):347-353.e1. PubMed ID: 38418264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases Pretreated with EGFR-Tyrosine Kinase Inhibitors.
    Saboundji K; Auliac JB; Pérol M; François G; Janicot H; Marcq M; Dubos-Arvis C; Renault A; Guisier F; Odier L; Gervais R; Chouaïd C
    Target Oncol; 2018 Aug; 13(4):501-507. PubMed ID: 30039345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Survival analysis of different kinds of tyrosine kinase inhibitors in the treatment of patients with epidermal growth factor receptor mutated non-small cell lung cancer and leptomeningeal metastasis].
    Xu HY; Chen HQ; Kong JX; Zhang Y; Liu S; Yang GJ; Wang Y
    Zhonghua Yi Xue Za Zhi; 2022 Feb; 102(6):399-405. PubMed ID: 35144338
    [No Abstract]   [Full Text] [Related]  

  • 8. Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Wu YL; Zhao Q; Deng L; Zhang Y; Zhou XJ; Li YY; Yu M; Zhou L; Zou BW; Lu Y; Liu YM
    Lung Cancer; 2019 Jan; 127():1-5. PubMed ID: 30642536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy analysis of Osimertinib treatment for a patient with leptomeningeal metastasis of EGFR+ non-small cell lung cancer without the T790M mutation.
    Hu X; Chen W; Li X; Zhao C; Zhang C; Xiong F; Wu H
    Ann Palliat Med; 2019 Nov; 8(5):525-531. PubMed ID: 31865717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcomes of Patients with Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer with Leptomeningeal Metastasis in the Modern Target Therapy Era.
    Wang Y; Li J; Liu T; Ge M; Ji X; Chu Z; Zhan Q; Liang X; Zhou X
    World Neurosurg; 2023 Feb; 170():e500-e509. PubMed ID: 36396052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis.
    Li D; Song Z; Dong B; Song W; Cheng C; Zhang Y; Zhang W
    J Clin Pharm Ther; 2022 Jan; 47(1):24-32. PubMed ID: 34309914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
    Wang X; Cai J; Zeng Z; Liu A
    BMC Cancer; 2021 Jul; 21(1):873. PubMed ID: 34330231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole brain radiation therapy does not improve the overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastasis.
    Yan W; Liu Y; Li J; Han A; Kong L; Yu J; Zhu H
    Radiat Oncol; 2019 Sep; 14(1):168. PubMed ID: 31521171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
    Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T
    Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
    Nadler E; Pavilack M; Espirito JL; Clark J; Fernandes A
    Adv Ther; 2020 Feb; 37(2):946-954. PubMed ID: 31955357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.
    Kuiper JL; Hendriks LE; van der Wekken AJ; de Langen AJ; Bahce I; Thunnissen E; Heideman DA; Berk Y; Buijs EJ; Speel EJ; Krouwels FH; Smit HJ; Groen HJ; Dingemans AM; Smit EF
    Lung Cancer; 2015 Sep; 89(3):255-61. PubMed ID: 26117231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis.
    Chiang CL; Ho HL; Yeh YC; Lee CC; Huang HC; Shen CI; Luo YH; Chen YM; Chiu CH; Chou TY
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):5-14. PubMed ID: 36318332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI.
    Kim HR; Jo H; Kim H; Hong J; Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ
    Cancer Res Treat; 2023 Jan; 55(1):344-349. PubMed ID: 35344648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.